CLINICAL TRIALS PROFILE FOR EVOMELA

All Clinical Trials for EVOMELA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004088 ↗	Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma	Completed	National Cancer Institute (NCI)	Phase 2	1999-04-13	RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy drugs and kill more cancer cells. Biological therapies, such as interferon alfa, use different ways to stimulate the immune system and stop cancer cells from growing. Thalidomide may stop the growth of cancer cells by stopping blood flow to the tumor. Pamidronate may help to reduce the side effects of treatment for multiple myeloma. PURPOSE: This phase II trial is studying combination chemotherapy, peripheral stem cell transplantation, biological therapy, pamidronate, and thalidomide to see how well they work in treating patients with stage I, stage II, or stage III multiple myeloma.
NCT00004088 ↗	Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma	Completed	City of Hope Medical Center	Phase 2	1999-04-13	RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy drugs and kill more cancer cells. Biological therapies, such as interferon alfa, use different ways to stimulate the immune system and stop cancer cells from growing. Thalidomide may stop the growth of cancer cells by stopping blood flow to the tumor. Pamidronate may help to reduce the side effects of treatment for multiple myeloma. PURPOSE: This phase II trial is studying combination chemotherapy, peripheral stem cell transplantation, biological therapy, pamidronate, and thalidomide to see how well they work in treating patients with stage I, stage II, or stage III multiple myeloma.
NCT00777881 ↗	Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma	Completed	Columbia University	Phase 4	2012-09-01	The study is being done to compare the combination of lenalidomide and dexamethasone followed by autologous peripheral blood stem cell transplant (PBSCT) and lenalidomide and dexamethasone without PBSCT in patients with untreated multiple myeloma. This comparison will include how the subjects respond to each study treatment combination, and what side effects are caused by each combination.
NCT00777881 ↗	Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma	Completed	University of Pittsburgh	Phase 4	2012-09-01	The study is being done to compare the combination of lenalidomide and dexamethasone followed by autologous peripheral blood stem cell transplant (PBSCT) and lenalidomide and dexamethasone without PBSCT in patients with untreated multiple myeloma. This comparison will include how the subjects respond to each study treatment combination, and what side effects are caused by each combination.
NCT00890552 ↗	A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis	Completed	Celgene Corporation	N/A	2009-04-01	This open-label trial will evaluate the use of lenalidomide; melphalan; and dexamethasone (MDR) to treat newly diagnosed or relapsed AL amyloidosis, over the course of nine 28-day cycles.
NCT00890552 ↗	A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis	Completed	Stanford University	N/A	2009-04-01	This open-label trial will evaluate the use of lenalidomide; melphalan; and dexamethasone (MDR) to treat newly diagnosed or relapsed AL amyloidosis, over the course of nine 28-day cycles.

Clinical Trial Conditions for EVOMELA

Condition Name

Condition Name for EVOMELA
Intervention	Trials
Multiple Myeloma	7
Leukemia	3
Myelodysplastic Syndrome	3
Refractory Plasma Cell Myeloma	2

Condition MeSH

Condition MeSH for EVOMELA
Intervention	Trials
Multiple Myeloma	11
Neoplasms, Plasma Cell	10
Preleukemia	3
Leukemia	3

Clinical Trial Locations for EVOMELA

Trials by Country

Trials by Country for EVOMELA
Location	Trials
United States	82
Canada	5
Puerto Rico	1

Trials by US State

Trials by US State for EVOMELA
Location	Trials
Ohio	5
New York	5
Texas	5
California	4
Pennsylvania	3

Clinical Trial Progress for EVOMELA

Clinical Trial Phase

Clinical Trial Phase for EVOMELA
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	1
Phase 2	11

Clinical Trial Status

Clinical Trial Status for EVOMELA
Clinical Trial Phase	Trials
Recruiting	9
Completed	8
Active, not recruiting	1

Clinical Trial Sponsors for EVOMELA

Sponsor Name

Sponsor Name for EVOMELA
Sponsor	Trials
National Cancer Institute (NCI)	9
Spectrum Pharmaceuticals, Inc	4
M.D. Anderson Cancer Center	3

Sponsor Type

Sponsor Type for EVOMELA
Sponsor	Trials
Other	21
Industry	11
NIH	9